Anti‑proliferative and pro‑apoptotic effects of rosemary and constituent terpenoids in a model for the HER‑2‑enriched molecular subtype of clinical breast cancer

Telang,Nitin

doi:10.3892/ol.2018.9238

Anti‑proliferative and pro‑apoptotic effects of rosemary and constituent terpenoids in a model for the HER‑2‑enriched molecular subtype of clinical breast cancer

Authors:
- Nitin Telang
View Affiliations

Affiliations: Cancer Prevention Research Program, Palindrome Liaisons Consultants, Montvale, NJ 07645‑1559, USA
Published online on: July 31, 2018 https://doi.org/10.3892/ol.2018.9238
Pages: 5489-5497

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neoadjuvant treatment options for human epidermal growth factor receptor‑2 (HER‑2)‑enriched and luminal B molecular subtypes of clinical breast cancer include HER‑2‑targeted therapy with chemotherapy or anti‑hormonal therapy. These treatment options result in systemic toxicity and acquired tumor resistance. Minimally toxic naturally occurring phytochemicals may represent testable alternatives to conventional therapy. HER‑2‑overexpressing tumorigenic human mammary epithelial 184‑B5/HER cells represent a model for the HER‑2‑enriched breast cancer subtype. Non‑fractionated rosemary extract (RME) and constituent phenolic terpenoids ursolic acid (UA), carnosol (CSOL) and carnosic acid (CA) represented the test agents. Anchorage‑independent (AI) proliferation, cell cycle progression, cellular apoptosis and expression of cell cycle‑regulatory and apoptosis‑specific proteins represented the mechanistic end point biomarkers. Relative to the parental non‑tumorigenic 184‑B5 cells, tumorigenic 184‑B5/HER cells exhibited decreased population doubling, increased saturation density, accelerated cell cycle progression and downregulated cellular apoptosis, confirming the loss of homeostatic control of proliferation. Treatment with the test agents resulted in a dose‑dependent decrease in AI colony number, indicating a decrease in cancer risk. Mechanistically, RME and UA inhibited G1‑S phase transition resulting in an increased G1:S+G2/M ratio and decreased cyclin D1 expression. The pro‑apoptotic effect of RME and UA was indicated by increased sub‑G0 (apoptotic) cell population, and relevant reciprocal modulation, as demonstrated by decreased anti‑apoptotic B‑cell lymphoma‑2 (Bcl‑2) and increased pro‑apoptotic Bcl‑2‑associated X protein expression. In contrast, treatment with CA and CSOL resulted in cytostatic G2/M arrest and an increase in cyclin B1 expression; thus, naturally‑occurring rosemary and its constitutive terpenoids re‑establish homeostatic control of proliferation and decrease cancer risk via distinct mechanisms. These data validate an experimental approach to prioritize efficacious natural compounds as testable alternatives for conventional chemo‑endocrine and HER‑2‑targeted therapies in HER‑2‑enriched breast cancer.

View Figures

View References

1	Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, vande Rijn M, Jefrrey SS, et al: Gene expression patterns in breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
2	Pierce JH, Arnstein P, DiMarco E, Artrip J, Kraus MH, Lonardo F, DiFiore PP and Aaronson SA: Oncogenic potential of erB-2 in human mammary epithelial cells. Oncogene. 6:1189–1194. 1991.PubMed/NCBI
3	Telang NT, Narayanan R, Bradlow HL and Osborne MP: Coordinated expression of intermediate markers for tumorigenic transformation in Ras transfected mouse mammary epithelial cells. Breast Cancer Res Treat. 18:155–163. 1991. View Article : Google Scholar : PubMed/NCBI
4	Telang NT, Osborne MP, Sweterlitsch L and Narayanan R: Neoplastic transformation of mouse mammary epithelial cells by deregulated myc expression. Cell Regul. 1:863–872. 1990. View Article : Google Scholar : PubMed/NCBI
5	Johnston SRD and Dowsett M: Aromatase inhibitors for breast cancer: Lessons from the laboratory. Nat Rev Cancer. 3:821–831. 2003. View Article : Google Scholar : PubMed/NCBI
6	Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al: Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI
7	Baselga J and Swain SM: Novel anti-cancer targets: Revisiting ERB2 and discovering ERB3. Nat Rev Cancer. 9:463–475. 2009. View Article : Google Scholar : PubMed/NCBI
8	Lee KW, Bode AM and Dong Z: Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer. 11:211–218. 2011. View Article : Google Scholar : PubMed/NCBI
9	Ye I, Jia Y, JI KE, Sanders AJ, Xue K, Ji J, Mason MD and Jiang WG: Traditional Chinese medicine in the prevention and treatment of breast cancer and cancer metastasis. Oncol Lett. 10:1240–1250. 2015. View Article : Google Scholar : PubMed/NCBI
10	Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM and Dannenberg AJ: Resveratrol inhibits cyclo-oxygenase-2 transcription and activity in phorbol ester treated human mammary epithelial cells. J Biol Chem. 273:21875–21882. 1998. View Article : Google Scholar : PubMed/NCBI
11	Katdare M, Osborne MP and Telang NT: Soy isoflavone genestein modulates cell cycle progression and induces apoptosis in HER2/neu oncogene expressing human breast epithelial cells. Int J Oncol. 21:809–815. 2002.PubMed/NCBI
12	Katdare M, Osborne MP and Telang NT: Novel cell culture models for prevention of human breast cancer (Review). Int J Oncol. 22:509–515. 2003.PubMed/NCBI
13	Jinno H, Steiner MG, Nason-Burchenal K, Osborne MP and Telang NT: Preventive efficacy of receptor class selective retinoids on HER-2/neu oncogene expressing pre-neoplastic human mammary epithelial cells. Int J Oncol. 21:127–134. 2002.PubMed/NCBI
14	Subbaramaiah K, Michaluart P, Sporn MB and Dannenberg AJ: Ursolic acid inhibits cyclo-oxygenase-2 transcription in human mammary epithelial cells. Cancer Res. 60:2399–2404. 2000.PubMed/NCBI
15	Subbaramaiah K, Cole PA and Dannenberg AJ: Retinoids and carnosol suppress cyclo-oxygenase-2 transcription by CREB-binding protein/p300-dependent and -independent mechanisms. Cancer Res. 62:2522–2530. 2002.PubMed/NCBI
16	Manez S, Recio MC, Giner RM and Ríos JL: Effect of selected triterpenoids on chronic dermal inflammation. Eur J Pharmacol. 334:103–105. 1997. View Article : Google Scholar : PubMed/NCBI
17	Huang MT, Ho CT, Wang ZY, Ferraro T, Lou YR, Stauber K, Ma W, Georgiadis C, Laskin JD and Conney AH: Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res. 54:701–708. 1994.PubMed/NCBI
18	Stampfer MR and Bartley JC: Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to Benzo (α) pyrene. Proc Natl Acad Sci USA. 82:2394–2398. 1985. View Article : Google Scholar : PubMed/NCBI
19	Zhai YF, Biettenmiller H, Wang B, Gould MN, Oakley C, Esselman WL and Welsch CW: Increased expression of specific tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. Cancer Res. 53:2272–2278. 1993.PubMed/NCBI
20	Musgrove EA and Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 9:631–643. 2009. View Article : Google Scholar : PubMed/NCBI
21	Wang J, Gildea JJ and Yue W: Aromatase over-expression induces malignant changes in estrogen receptor-α negative MCF-10A cells. Oncogene. 32:5233–5240. 2013. View Article : Google Scholar : PubMed/NCBI
22	Telang N: Putative cancer initiating stem cells in cell culture models for molecular subtypes of clinical breast cancer. Oncol Lett. 10:3840–3846. 2015. View Article : Google Scholar : PubMed/NCBI
23	Telang N: Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer. Biomed Rep. 7:199–204. 2017. View Article : Google Scholar : PubMed/NCBI
24	Plouzek CA, Ciolino HP, Clarke R and Yeh GC: Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. Eur J Cancer. 35:1541–1545. 1999. View Article : Google Scholar : PubMed/NCBI
25	Kassi E, Sourlingas TG, Spiliotaki M, Papoutsi Z, Prastinis H, Aligiannis N and Moutsatsou P: Ursolic acid triggers apoptosis and BCL-2 down-regulation in MCF-7 breast cancer cells. Cancer Investig. 27:723–733. 2009. View Article : Google Scholar
26	Lou J, Hu YL and Wang H: Ursolic acid inhibits breast cancer growth by inhibiting proliferation, inducing autophagy and apoptosis, and suppressing inflammatory responses via the PI3K/AKT and NFkB signaling pathways in vitro. Exp Ther Med. 14:3623–3631. 2017. View Article : Google Scholar : PubMed/NCBI
27	Wang CZ, Calway TD, Wen XD, Smith J, Yu C, Wang Y, Mehendale SR and Yuan CS: Hydrophobic flavonoids from Scutellaria baicelensis induce colorectal cancer cell apoptosis through a mitochondrial-mediated pathway. Int J Oncol. 42:1018–1026. 2013. View Article : Google Scholar : PubMed/NCBI
28	Vissanji JM, Thompson DG and Padfield PJ: Induction of G2/M phase cell cycle arrest by carnosol and carnosic acid is associated with alteration of cyclin A and cyclin B1 levels. Cancer Lett. 237:130–136. 2006. View Article : Google Scholar : PubMed/NCBI
29	Sabbaghi MA, Gil-Gomez G, Guardia C, Servitja S, Arpi O, Garcia-Alonso S, Menedez S, Arumi-Uria M, Serrano L, Salido M, et al: Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER-2 positive breast cancer. Clin Cancer Res. 23:7006–7019. 2017. View Article : Google Scholar : PubMed/NCBI
30	D'Alesio C, Bellese G, Gagliani MC, Aiello C, Grasselli E, Marcocci G, Bisio A, Tavella S, Daniele T, Cortese K and Castagnola P: Cooperative anti-tumor activities of carnosic acid and Trastuzumab in ERBB2⁺ breast cancer cells. J Exp Clin Cancer Res. 36:1542017. View Article : Google Scholar : PubMed/NCBI